Otonomy

OTIC NASDAQ
2.230
-0.070
-3.04%
休市 16:00 08/23 EDT
开盘
2.250
昨收
2.300
最高
2.270
最低
2.200
成交量
2.01万
成交均量(3M)
3.41万
52周最高
3.200
52周最低
1.500
换手率
0.07%
市值
6,856.90万
分时
5日
1月
3月
1年
5年

相关股票

微牛行情栏目提供Otonomy OTIC股票价格,Otonomy股票实时行情,公司简介,财报信息,股本结构等,掌握美港股行情走势,开盘价,收盘价,总市值,换手率,市盈率,收益率等数据,及时把握美股港股投资机会。

公司介绍

Otonomy, Inc. is a biopharmaceutical company. The Company focuses on the development and commercialization of therapeutics for diseases and disorders of the ear. The Company's product candidates include OTIPRIO, OTO-104 and OTO-311. OTIPRIO is a single-dose, physician-administered antibacterial, which is used for the treatment of pediatric patients with bilateral otitis media with effusion undergoing tympanostomy tube placement (TTP) surgery and is available for commercial purchase. OTO-104 is a sustained-exposure formulation of the steroid dexamethasone in development for the treatment of Meniere's disease and other inner ear conditions. OTO-311 is a sustained-exposure formulation of the N-Methyl-D-Aspartate (NMDA) receptor antagonist gacyclidine in development for the treatment of tinnitus. It also has various other product candidates, which target sensorinerual hearing loss, including age-related hearing loss, also known as presbycusis.
展开 >

最近浏览

名称
价格
涨跌幅